Drug
Avapritinib clinical trials
Also written BLU-285 and AYVAKIT.
- studies test it
- 18
- open now
- 9
- in phase 3
- 1
- first study started
- 2015
Keep track of what changes. Save the Avapritinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Brand
Combined with it in one product
Studies by the year they started
18 studies that test it; most in 2024 (4)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2016 | 1 |
| 2018 | 2 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 3 |
| 2024 | 4 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 6
- Phase 2
- 10
- Phase 3
- 1
- Phase 4
- 2
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 8
Blueprint Medicines Corporation (9) · Institute of Hematology & Blood Diseases Hospital, China (2) · CStone Pharmaceuticals (1) · Ruijin Hospital (1) · Centre Leon Berard (1) · M.D. Anderson Cancer Center (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Children's Hospital of Soochow University (1)
Often tested with
Tested in the same studies.
Venetoclax (2) · Azacitidine (2) · Trametinib (2) · Midazolam (1) · Ivosidenib (1) · Gilteritinib (1) · Daunorubicin (1) · Cytarabine (1)
Studies
Open first, then newest update. How each study uses Avapritinib is read from its arms, and is right about nine times in ten.
Testing it · 18
- MRD-positive AML Clinical StudyRecruitingNot applicableInstitute of Hematology & Blood Diseases Hospital, ChinaNCT07131059Written as Avapritinib
- A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.RecruitingPhase 2Centre Leon BerardNCT04116541Written as Avapritinib
- Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid TumorsRecruitingPhase 2M.D. Anderson Cancer CenterNCT04771520Written as Avapritinib
- Avapritinib With Decitabine in Patients With SM-AHNRecruitingPhase 1H. Lee Moffitt Cancer Center and Research InstituteNCT06327685Written as Avapritinib
- Avapritinib Rollover StudyRecruitingPhase 4Blueprint Medicines CorporationNCT06748001Written as Avapritinib
- Avapritinib Combined With Azacitidine and Venetoclax in the Treatment of Relapsed AML After Allo-HSCTRecruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT06783790Written as Avapritinib, azacitidine, Venetoclax
- Avapritinib Maintenance for AML With KIT MutationsNot yet recruitingPhase 2Ruijin HospitalNCT06765915Written as Avapritinib
- Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT MutationRecruitingPhase 2Children's Hospital of Soochow UniversityNCT06316960Written as Avapritinib
- Avapritinib in CBF-AML With KIT MutationsRecruitingPhase 2The First Affiliated Hospital of Soochow UniversityNCT05821738Written as Avapritinib
- (PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic MastocytosisCompletedPhase 2Blueprint Medicines CorporationNCT03580655Written as Avapritinib
- (PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic MastocytosisActive, not recruitingPhase 2Blueprint Medicines CorporationNCT03731260Written as Avapritinib
- A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA SignalingCompletedPhase 1/2Blueprint Medicines CorporationNCT04773782Written as avapritinib
- A Drug-drug Interaction Study of Avapritinib and MidazolamCompletedPhase 1Blueprint Medicines CorporationNCT04908176Written as Avapritinib
- Study for Patients Previously Treated in Avapritinib Clinical TrialsCompletedPhase 4Blueprint Medicines CorporationNCT04825574Written as Avapritinib
- A Study of CS3007 in Subjects With Gastrointestinal Stromal TumorCompletedPhase 1/2CStone PharmaceuticalsNCT04254939Written as CS3007 (BLU-285)
- (EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid MalignanciesCompletedPhase 1Blueprint Medicines CorporationNCT02561988Written as Avapritinib
- (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GISTCompletedPhase 3Blueprint Medicines CorporationNCT03465722Written as avapritinib
- (NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid TumorsCompletedPhase 1Blueprint Medicines CorporationNCT02508532Written as Avapritinib
Given in every arm · 1 — Avapritinib is usual care beside what is tested
Codes
What other systems call Avapritinib · ClinicalTrials.gg INT006892
- MeSH (NLM) D000099289AvapritinibOne source NLM
- UNII (FDA) 513P80B4YJAVAPRITINIBConfirmed FDA, NLM, Wikidata
- RxNorm 2272107Confirmed FDA, Wikidata
- Wikidata Q29213676avapritinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C123827AvapritinibOne source FDA
- DrugBank DB15233One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000099289 | Avapritinib | One source NLM |
| UNII (FDA) | 513P80B4YJ | AVAPRITINIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2272107 | — | Confirmed FDA, Wikidata |
| Wikidata | Q29213676 | avapritinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C123827 | Avapritinib | One source FDA |
| DrugBank | DB15233 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.